Study Evaluating the Effect of UCB8600 on Mast Cell Activation in the Human Gut

Study evaluating the effect of UCB8600 on mast cell activation in the human gut: IBS is a disease characterized by abdominal pain and a change in stool. Treatment is limited to an adapted life style, dietary changes and medication to lessen cramps (spasmolytica), all of which have seen limited to no clinical success. Recently, we were able to demonstrate that mast cells play an active role in IBS symptoms. More specifically, they set histamine free when activated which heightens nerve sensitivity in the intestines which probably contributes to the abdominal pain. A new product called "UCB8600" is hypothesized to be able to counteract this by causing less mast cells to be activated. In this study we'll test this by administering UCB8600 on intestinal tissue and see if there is less mast cell activation. If the study produces good results, this new product could potentially be used as a treatment for IBS in the future.

NCT Number	NCT07655375
Lead Sponsor	Guy Boeckxstaens Collaborators: UCB S.A. - Pharma Sector
Conditions	IBS (Irritable Bowel Syndrome)
Enrollment	60 participants
Start Date	2026-08
Primary Completion	2027-10 (estimated)
Study Completion	2028-04 (estimated)
Updated on ClinicalTrials.gov	2026-08-11